The global enzyme-linked immunosorbent assays (ELISA) market is expected to gain impetus from the rising incidence of chronic and infectious diseases. This information is published by Fortune Business Insights™ in an upcoming report, titled, “Enzyme-Linked Immunosorbent Assays Market” Share and Global Trend By Test Type (Direct ELISA, Sandwich ELISA, Competitive ELISA, Reverse ELISA), By Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantification), By End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutions), and Geography Forecast till 2026.” The report further mentions that various technological advancements are taking place in the field of ELISA.
Additionally, the increasing demand for vitro diagnostics and ELISA tests for early detection are projected to propel the ELIS market growth during the forthcoming years.
Request a Sample Copy of the Research Report:
Rising Research & Development Activities to Favor Growth in Europe & North America
The market is geographically fragmented into the Middle East and Africa, Latin America, Asia Pacific, Europe, and North America. Out of these regions, at present, Europe and North America are two of the largest markets. They are anticipated to acquire maximum ELISA market share in the coming years. This growth is attributable to the rising sophistication of ELISA and an increasing number of research and development activities going on in the region. These factors are further resulting in the higher usage of the tests.
Asia Pacific, on the other hand, would experience considerable growth. Japan is projected to offer the greatest market opportunities during the forecast period. It would occur because of the country’s increasing healthcare expenditure and the highly developed healthcare system. These factors would help the region in increasing its ELISA market size in the coming years.
Key Players Aim to Conduct Trials & Launch Novel Products to Gain Competitive Edge
Renowned players present in the market are trying to gain the maximum enzyme-linked immunosorbent assays market revenue. They are doing so by launching new innovative products and by conducting multiple research and development activities. Organizations, namely, CDC and WHO, are also participating in unveiling new ELISA test kits to help the doctors in diagnosing diseases. Below are a couple of the latest key industry developments:
- March 2018: BARD1 Life Sciences, a medical technology company, headquartered in Australia, declared that its BARD1-Ovarian test has proved to be a success in providing high accuracy in detecting ovarian cancer. It is a non-invasive diagnostic tool. The company’s independent study examined the strength of the algorithm on 27 healthy controls and 82 ovarian cancers. It is a ELISA-based blood test that can identify ovarian cancer in the early stage. The tool measures the autoantibodies present in the blood in conjunction with the company’s original algorithm to come up with a score that can detect the presence of ovarian cancer.
July 2018: The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) announced the launch of their new version of ELISA test kit called ELISA YF MAC HD. It is required for laboratory confirmation of yellow fever, which is often based on the patient’s dates and places of travel as well as clinical symptoms. The test would enable doctors to identify anti-YFV IgM antibodies that are to be presented in the patient’s body following a vaccine injection and a viral infection. It can also be used for the diagnosis of other diseases, such as HIV or malaria. At present, the ELISA tests available in the market are not readily purchasable. Laboratories will have to get the components of the test from various sources and create their protocols. However, the new kit will be able to develop a standardized platform for yellow fever IgM testing.
Leading Players operating in the Enzyme-Linked Immunosorbent Assays Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Ortho-Clinical Diagnostics
- Thermo Fisher Scientific. Inc.
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- ZEUS Scientific, Inc.
- Other key market players
Segmentation of the Global Enzyme-Linked Immunosorbent Assays (ELISA) Market
By Test Type
- Direct ELISA
- Sandwich ELISA
- Competitive ELISA
- Reverse ELISA
- Infectious Diseases
- Protein Quantification
By End User
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutions
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/enzyme-linked-immunosorbent-assays-market-100649
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Related Reports :